Multicenter Trial For Patients With Acute Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- Registration Number
- NCT00035503
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Brief Summary
The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
Stuart Weisman
🇺🇸Palo Alto, California, United States
University of Colorado Medical Center
🇺🇸Denver, Colorado, United States
Washington Hospital Center
🇺🇸Washington, District of Columbia, United States
Mark Lamet
🇺🇸Hollywood, Florida, United States
Wayne Schonfeld
🇺🇸Hollywood, Florida, United States
Mount Sinai Medical Center
🇺🇸Miami Beach, Florida, United States
University of Chicago Hospital Medical Center
🇺🇸Chicago, Illinois, United States
Gerald Dryden
🇺🇸Louisville, Kentucky, United States
Richard MacDermott
🇺🇸Albany, New York, United States
Hillary Steinhart
🇨🇦Toronto, Ontario, Canada
Scroll for more (1 remaining)Stuart Weisman🇺🇸Palo Alto, California, United States